Show simple item record

dc.contributor.authorXuan, J
dc.contributor.authorPearson, RB
dc.contributor.authorSanij, E
dc.date.accessioned2020-11-27T00:41:10Z
dc.date.available2020-11-27T00:41:10Z
dc.date.issued2020-09-02
dc.identifierpii: 1805256
dc.identifier.citationXuan, J., Pearson, R. B. & Sanij, E. (2020). CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer. MOLECULAR & CELLULAR ONCOLOGY, 7 (6), https://doi.org/10.1080/23723556.2020.1805256.
dc.identifier.issn2372-3556
dc.identifier.urihttp://hdl.handle.net/11343/252553
dc.description.abstractAcquired drug resistance leads to poor clinical outcome in high grade serous ovarian cancer (HGSOC). We have demonstrated the efficacy of the novel drug CX-5461 in HGSOC is mediated through destabilization of DNA replication forks. The data highlights the potential of CX-5461 in overcoming a general mechanism of chemotherapeutic resistance.
dc.languageEnglish
dc.publisherTAYLOR & FRANCIS INC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleCX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
dc.typeJournal Article
dc.identifier.doi10.1080/23723556.2020.1805256
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.source.titleMolecular & cellular oncology
melbourne.source.volume7
melbourne.source.issue6
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1464407
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671053
melbourne.contributor.authorSanij, Elaine
dc.identifier.eissn2372-3556
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record